These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 27643437)

  • 1. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
    Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y
    Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
    Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J
    Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.
    Jin Y; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Zhou J; Pan J
    Clin Cancer Res; 2017 Jun; 23(11):2842-2855. PubMed ID: 27852702
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
    Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
    Liu C; Nie D; Li J; Du X; Lu Y; Li Y; Zhou J; Jin Y; Pan J
    Cancer Res; 2018 Mar; 78(6):1522-1536. PubMed ID: 29321163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
    Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J
    Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525
    [No Abstract]   [Full Text] [Related]  

  • 12. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
    Xu X; Zhang X; Liu Y; Yang L; Huang S; Lu L; Wang S; Guo Q; Zhao L
    Oncotarget; 2016 Apr; 7(17):24436-54. PubMed ID: 27027438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
    Hu Y; Chen Y; Douglas L; Li S
    Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
    Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
    Willmann M; Sadovnik I; Eisenwort G; Entner M; Bernthaler T; Stefanzl G; Hadzijusufovic E; Berger D; Herrmann H; Hoermann G; Valent P; Rülicke T
    Exp Hematol; 2018 Jan; 57():50-59.e6. PubMed ID: 29031704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
    Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
    Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
    Zhang B; Strauss AC; Chu S; Li M; Ho Y; Shiang KD; Snyder DS; Huettner CS; Shultz L; Holyoake T; Bhatia R
    Cancer Cell; 2010 May; 17(5):427-42. PubMed ID: 20478526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and cellular bases of chronic myeloid leukemia.
    Chen Y; Peng C; Li D; Li S
    Protein Cell; 2010 Feb; 1(2):124-32. PubMed ID: 21203982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
    Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
    Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.